{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:39:23Z","timestamp":1789155563647,"version":"build-2803163510"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFA0922400"],"award-info":[{"award-number":["2025YFA0922400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2025YC29"],"award-info":[{"award-number":["2025YC29"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304291"],"award-info":[{"award-number":["82304291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmech.2026.118761","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:08:07Z","timestamp":1773158887000},"page":"118761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cyclopropyl as a versatile tool in the development of kinase-targeted therapeutics"],"prefix":"10.1016","volume":"309","author":[{"given":"Wenwu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuona","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5944","authenticated-orcid":false,"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118761_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrg2707","article-title":"Kinase mutations in human disease: interpreting genotype-phenotype relationships","volume":"11","author":"Lahiry","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.118761_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2174\/0929867302666220216234752","article-title":"Biologically active cyclopropanes and cyclopropenes","volume":"2","author":"Salaiin","year":"1995","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib6","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1021\/cr0505369","article-title":"Three-membered-ring-based molecular architectures","volume":"106","author":"de Meijere","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118761_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1021\/cr0100188","article-title":"Biosynthesis and metabolism of cyclopropane rings in natural compounds","volume":"103","author":"Wessjohann","year":"2003","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118761_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/prac.18820260125","volume":"26","author":"Freund","year":"1882","journal-title":"J. Prakt. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib9","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1021\/acs.jmedchem.2c00473","article-title":"Rings in clinical trials and drugs: present and future","volume":"65","author":"Shearer","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib10","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1021\/acs.jmedchem.3c01486","article-title":"Discovery of MK-1468: a potent, kinome-selective, brain-penetrant amidoisoquinoline LRRK2 inhibitor for the potential treatment of Parkinson's disease","volume":"66","author":"Kattar","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib11","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/acsmedchemlett.0c00249","article-title":"Stereochemical differences in fluorocyclopropyl amides enable tuning of btk inhibition and off-target activity","volume":"11","author":"Crawford","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113158","article-title":"Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase","volume":"213","author":"Martinez-Gualda","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41570-023-00499-6","article-title":"Metal-catalysed C\u2013C bond formation at cyclopropanes","volume":"7","author":"Gabbey","year":"2023","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2026.118761_bib14","doi-asserted-by":"crossref","first-page":"24503","DOI":"10.1021\/jacs.4c07039","article-title":"Anti-selective cyclopropanation of nonconjugated alkenes with diverse pronucleophiles via directed nucleopalladation","volume":"146","author":"Ni","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118761_bib15","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1038\/s41598-020-59805-7","article-title":"Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer's disease","volume":"10","author":"Lalut","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118761_bib16","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \"Cyclopropyl Fragment\" is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update","author":"Roskoski","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/d41573-025-00188-7","article-title":"FDA approves 100th small-molecule kinase inhibitor","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020566","article-title":"The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification","volume":"22","author":"Wells","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118761_bib20","doi-asserted-by":"crossref","first-page":"D529","DOI":"10.1093\/nar\/gkaa853","article-title":"The dark kinase knowledgebase: an online compendium of knowledge and experimental results of understudied kinases","volume":"49","author":"Berginski","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118761_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2026.118761_bib24","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site kinase inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2026.118761_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/anie.197908093","article-title":"Bonding properties of cyclopropane and their chemical consequences","volume":"18","author":"De Meijere","year":"1979","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118761_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/cr00091a005","article-title":"Use of cyclopropanes and their derivatives in organic synthesis","volume":"89","author":"Wong","year":"1989","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118761_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/ar020230d","article-title":"Bond dissociation energies of organic molecules","volume":"36","author":"Blanksby","year":"2003","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib29","doi-asserted-by":"crossref","first-page":"20823","DOI":"10.1021\/jacs.4c04695","article-title":"Proteome-wide ligand and target discovery by using strain-enabled cyclopropane electrophiles","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118761_bib30","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1021\/jo980804l","article-title":"Ring strain and hydrogen bond acidity","volume":"63","author":"Alkorta","year":"1998","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib31","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00214-007-0353-z","article-title":"Non-alkane behavior of cyclopropane and its derivatives: characterization of unconventional hydrogen bond interactions","volume":"118","author":"Galano","year":"2007","journal-title":"Theor. Chem. Acc."},{"key":"10.1016\/j.ejmech.2026.118761_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1039\/D0MD00370K","article-title":"Put a ring on it: application of small aliphatic rings in medicinal chemistry","volume":"12","author":"Bauer","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib34","volume":"2","author":"Greb","year":"2016","journal-title":"Psoriasis, Nat Rev Dis Primers"},{"key":"10.1016\/j.ejmech.2026.118761_bib35","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib36","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118761_bib37","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib38","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-14-1105","article-title":"Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118761_bib39","first-page":"1","article-title":"Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC","volume":"43","author":"Ma","year":"2025","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.118761_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118761_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.118761_bib42","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cell.2015.06.023","article-title":"The Ras-Erk-ETS-signaling pathway is a drug target for longevity","volume":"162","author":"Slack","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118761_bib44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/ml200004g","article-title":"Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)","volume":"2","author":"Abe","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib46","first-page":"176","article-title":"Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ejmech.2026.118761_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118761_bib49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2026.118761_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02877-9","article-title":"Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis","volume":"20","author":"Nuesslein-Hildesheim","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2026.118761_bib51","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118761_bib52","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation Pan-TRK kinase inhibitors for the treatment of cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118761_bib54","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/1535-7163.MCT-15-0262","article-title":"BGB-283, a novel RAF kinase and EGFR inhibitor, displays potent antitumor activity in BRAF-mutated colorectal cancers","volume":"14","author":"Tang","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118761_bib55","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Open-label, dose-escalation\/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118761_bib56","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/1878-0261.12698","article-title":"RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors","volume":"14","author":"Yuan","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118761_bib57","doi-asserted-by":"crossref","first-page":"CT033","DOI":"10.1158\/1538-7445.AM2023-CT033","volume":"83","author":"Solomon","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118761_bib59","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1021\/acs.jmedchem.2c00527","article-title":"Discovery of clinical candidate NTQ1062 as a potent and bioavailable Akt inhibitor for the treatment of human tumors","volume":"65","author":"Ma","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118761_bib61","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Rudolph","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib62","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1021\/acs.jmedchem.4c02422","article-title":"Structure-based discovery of a highly selective, oral polo-like kinase 1 inhibitor with potent antileukemic activity","volume":"68","author":"Nie","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib63","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118761_bib64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.embor.embor776","article-title":"The Ark1\/Prk1 family of protein kinases: regulators of endocytosis and the actin cytoskeleton","volume":"4","author":"Smythe","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2026.118761_bib65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118761_bib66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acsmedchemlett.9b00399","article-title":"SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K","volume":"11","author":"Wells","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib67","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acsmedchemlett.4c00219","article-title":"Discovery and characterization of a chemical probe for cyclin-dependent kinase-like 2","volume":"15","author":"Bashore","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib68","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118761_bib69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1535-6108(03)00189-2","article-title":"BRAF as a potential therapeutic target in melanoma and other malignancies","volume":"4","author":"Tuveson","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118761_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib71","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1021\/jm300126x","article-title":"Design and synthesis of novel DFG-out RAF\/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds","volume":"55","author":"Okaniwa","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib72","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1021\/jm400778d","article-title":"Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives","volume":"56","author":"Okaniwa","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrm3737","article-title":"Regulated necrosis: the expanding network of non-apoptotic cell death pathways","volume":"15","author":"Vanden Berghe","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118761_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf2154","article-title":"Programmed necrosis in inflammation: toward identification of the effector molecules","volume":"352","author":"Wallach","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118761_bib75","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/bph.14653","article-title":"Identification of the Raf kinase inhibitor TAK\u2010632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3","volume":"176","author":"Chen","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118761_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128084","article-title":"Enantiomeric profiling of a chiral benzothiazole necroptosis inhibitor","volume":"43","author":"Zhu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acsmedchemlett.9b00065","article-title":"Identification of RIPK3 type II inhibitors using high-throughput mechanistic studies in hit triage","volume":"11","author":"Hart","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118761_bib79","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.bmcl.2015.03.046","article-title":"Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core","volume":"25","author":"Sivaprakasam","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib80","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.jmedchem.5b01550","article-title":"Discovery of isonicotinamides as highly selective, brain penetrable, and orally active glycogen synthase Kinase-3 inhibitors","volume":"59","author":"Luo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib81","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1021\/acs.jmedchem.3c00133","article-title":"Design, structure-activity relationships, and in vivo evaluation of potent and brain-penetrant Imidazo[1,2-b]pyridazines as glycogen synthase Kinase-3\u03b2 (GSK-3\u03b2) inhibitors","volume":"66","author":"Hartz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129143","article-title":"Structure-activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors","volume":"81","author":"Luo","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib83","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2019.02.001","article-title":"Synthesis and evaluation of novel GSK-3\u03b2 inhibitors as multifunctional agents against Alzheimer's disease","volume":"167","author":"Shi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib84","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/acschemneuro.0c00655","article-title":"((E)-N-(4-(((2-Amino-5-phenylpyridin-3-yl)imino)methyl)pyridin-2-yl)cyclopropanecarboxamide) ameliorated Abeta(1-42)-Induced Alzheimer's disease in SD rats by inhibiting oxidative stress and apoptosis","volume":"12","author":"Ding","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118761_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejmech.2019.04.035","article-title":"Pyridinylimidazoles as dual glycogen synthase kinase 3beta\/p38alpha mitogen-activated protein kinase inhibitors","volume":"175","author":"Heider","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","article-title":"Dual GSK-3beta\/AChE inhibitors as a new strategy for multitargeting anti-alzheimer's disease drug discovery","volume":"9","author":"Jiang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112751","article-title":"Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease","volume":"207","author":"Jiang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115940","article-title":"Discovery of potent glycogen synthase kinase 3\/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease","volume":"30","author":"Jiang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114095","article-title":"Discovery of novel \u03b2-carboline derivatives as selective AChE inhibitors with GSK-3\u03b2 inhibitory property for the treatment of Alzheimer's disease","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib90","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1021\/acs.jmedchem.8b00185","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics","volume":"61","author":"Jarhad","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib91","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","article-title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation","volume":"276","author":"G\u00f6ckler","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2026.118761_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer's disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib93","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118761_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7252882","article-title":"Tacrine derivatives in neurological disorders: focus on molecular mechanisms and neurotherapeutic potential","volume":"2022","author":"Mitra","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2026.118761_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105875","article-title":"Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property","volume":"126","author":"Liu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib96","doi-asserted-by":"crossref","first-page":"19342","DOI":"10.1039\/D2NJ03667C","article-title":"Novel tacrine derivatives as potential CDK9 inhibitors with low cholinesterase inhibitory properties: design, synthesis, and biological evaluation","volume":"46","author":"Liu","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib97","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jclinpath-2016-203629","article-title":"Gene of the month: axl","volume":"69","author":"Brown","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejmech.2026.118761_bib98","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejmech.2026.118761_bib99","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1021\/acs.jmedchem.0c02093","article-title":"Discovery of a pyrimidinedione derivative as a potent and orally bioavailable axl inhibitor","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2776(08)60451-4","article-title":"Involvement of the protein tyrosine kinase p56lck in T cell signaling and thymocyte development","volume":"56","author":"Anderson","year":"1994","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejmech.2026.118761_bib101","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.bmcl.2003.08.054","article-title":"Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck)","volume":"13","author":"Wityak","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib102","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1021\/acs.jmedchem.2c01361","article-title":"Targeting gatekeeper mutations for kinase drug discovery","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4161\/cl.21912","article-title":"PAK family kinases: physiological roles and regulation","volume":"2","author":"Zhao","year":"2012","journal-title":"Cell. Logist."},{"key":"10.1016\/j.ejmech.2026.118761_bib104","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acs.jmedchem.5b00572","article-title":"Structure-guided design of group I selective p21-Activated kinase inhibitors","volume":"58","author":"Crawford","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib105","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1128\/JB.00963-06","article-title":"The Ser\/Thr protein kinase PknB is essential for sustaining mycobacterial growth","volume":"188","author":"Fernandez","year":"2006","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2026.118761_bib106","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1021\/acsmedchemlett.7b00239","article-title":"Mtb PKNA\/PKNB dual inhibition provides selectivity advantages for inhibitor design to minimize host kinase interactions","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib107","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1021\/jm031145u","article-title":"3-Aminopyrazole inhibitors of CDK2\/cyclin A as antitumor agents. 1. Lead finding","volume":"47","author":"Pevarello","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib108","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","article-title":"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity","volume":"52","author":"Howard","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib110","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.V110.11.904.904","article-title":"A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies","volume":"110","author":"Ravandi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118761_bib111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","article-title":"A role for JAK2 mutations in myeloproliferative diseases","volume":"59","author":"Morgan","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2026.118761_bib112","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118761_bib113","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/acsmedchemlett.5b00225","article-title":"Structure-based design of selective janus kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine inhibitors","volume":"6","author":"Hart","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0092-8674(84)90309-X","article-title":"Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region","volume":"37","author":"Cuypers","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118761_bib115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118761_bib116","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib117","doi-asserted-by":"crossref","first-page":"16716","DOI":"10.1021\/acs.jmedchem.2c01550","article-title":"Identification of TUL01101: a novel potent and selective JAK1 inhibitor for the treatment of rheumatoid arthritis","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib118","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/med.21581","article-title":"Molecular design opportunities presented by solvent-exposed regions of target proteins","volume":"39","author":"Jiang","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118761_bib119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)00116-1","article-title":"Signal transduction by the JNK group of MAP kinases","volume":"103","author":"Davis","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118761_bib120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-2001-3107","article-title":"Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration","volume":"3","author":"Pei","year":"2001","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2026.118761_bib121","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0896-6273(95)90241-4","article-title":"p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system","volume":"14","author":"Abdi","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2026.118761_bib122","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.bmc.2013.02.021","article-title":"Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects","volume":"21","author":"Kim","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib123","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1021\/jm400072p","article-title":"Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors","volume":"56","author":"Peng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib124","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/372746a0","article-title":"Crystal structure of the tyrosine kinase domain of the human insulin receptor","volume":"372","author":"Hubbard","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118761_bib125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118761_bib126","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1021\/jm300847w","article-title":"PI3K\u03b4 and PI3K\u03b3 as targets for autoimmune and inflammatory diseases","volume":"55","author":"Cushing","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib127","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrd2145","article-title":"PI3Kgamma inhibition: towards an 'aspirin of the 21st century'","volume":"5","author":"R\u00fcckle","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118761_bib128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118761_bib129","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1021\/acs.jmedchem.8b00447","article-title":"Discovery of highly isoform selective orally bioavailable phosphoinositide 3-Kinase (PI3K)-\u03b3 inhibitors","volume":"61","author":"Pemberton","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41589-018-0215-0","article-title":"A class of highly selective inhibitors bind to an active state of PI3K\u03b3","volume":"15","author":"Gangadhara","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118761_bib131","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.1021\/acs.jmedchem.0c01203","article-title":"Discovery of potent and selective PI3K\u03b3 inhibitors","volume":"63","author":"Drew","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib132","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1021\/acs.jmedchem.1c01153","article-title":"Design, synthesis, and structure-activity relationship optimization of pyrazolopyrimidine amide inhibitors of phosphoinositide 3-Kinase \u03b3 (PI3K\u03b3)","volume":"65","author":"Mata","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib133","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1021\/acsmedchemlett.0c00387","article-title":"Discovery of potent and selective 7-Azaindole isoindolinone-based PI3K\u03b3 inhibitors","volume":"11","author":"Miles","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118761_bib134","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrm2970","article-title":"Molecular mechanisms of necroptosis: an ordered cellular explosion","volume":"11","author":"Vandenabeele","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118761_bib135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/SHK.0b013e31820b2db1","article-title":"The dual functions of receptor interacting protein 1 in fas-induced hepatocyte death during sepsis","volume":"35","author":"McNeal","year":"2011","journal-title":"Shock"},{"key":"10.1016\/j.ejmech.2026.118761_bib136","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/cdd.2012.90","article-title":"TRAIL induces necroptosis involving RIPK1\/RIPK3-dependent PARP-1 activation","volume":"19","author":"Jouan-Lanhouet","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.118761_bib137","article-title":"Potent and selective RIPK1 inhibitors targeting dual-pockets for the treatment of systemic inflammatory response syndrome and sepsis","volume":"61","author":"Yang","year":"2022","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118761_bib138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118761_bib139","doi-asserted-by":"crossref","first-page":"31984","DOI":"10.1021\/acsomega.0c04900","article-title":"Discovery of novel and highly selective cyclopropane ALK inhibitors through a fragment-assisted, structure-based drug design","volume":"5","author":"Fujimori","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118761_bib140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrm1401","article-title":"Polo-like kinases and the orchestration of cell division","volume":"5","author":"Barr","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118761_bib141","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1021\/jm400380m","article-title":"The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents","volume":"56","author":"Laufer","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib142","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/jm5005336","volume":"58","author":"Sampson","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0394","article-title":"Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease","volume":"9","author":"Le Pichon","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118761_bib144","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4155\/fmc.13.150","article-title":"Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions","volume":"5","author":"Ferraris","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib145","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/13543776.2016.1170810","article-title":"Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010-2015)","volume":"26","author":"Oetjen","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118761_bib146","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1021\/acs.jmedchem.9b00443","article-title":"Identification of N-Methyl nicotinamide and N-Methyl Pyridazine-3-Carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)","volume":"62","author":"Moslin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib147","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib148","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2010.177","article-title":"Non-canonical NF-\u03baB signaling pathway","volume":"21","author":"Sun","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib149","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1021\/acs.jmedchem.8b00678","article-title":"Scaffold-hopping approach to discover potent, selective, and efficacious inhibitors of NF-kappaB inducing kinase","volume":"61","author":"Blaquiere","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129277","article-title":"Filling a nick in NIK: extending the half-life of a NIK inhibitor through structure-based drug design","volume":"89","author":"Crawford","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087851","article-title":"Design and synthesis of a library of lead-like 2, 4-bisheterocyclic substituted thiophenes as selective Dyrk\/Clk inhibitors","volume":"9","author":"Schmitt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118761_bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2018.08.097","article-title":"Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: identification of the cyclopropylamide moiety as a key modification","volume":"158","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib153","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118761_bib154","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/jm500305p","article-title":"Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis","volume":"58","author":"Lou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib155","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bmcl.2014.12.091","article-title":"Discovery of 5-(1H-indol-5-yl)-1, 3, 4-thiadiazol-2-amines as potent PIM inhibitors","volume":"25","author":"Wu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib156","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1016\/j.bmcl.2013.09.055","article-title":"The optimization of aminooxadiazoles as orally active inhibitors of Cdc7","volume":"23","author":"Harrington","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib157","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bmcl.2014.12.067","article-title":"The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors","volume":"25","author":"Wurz","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118761_bib158","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/acs.jmedchem.6b00610","article-title":"Discovery and optimization of quinazolinone-pyrrolopyrrolones as potent and orally bioavailable pan-pim kinase inhibitors","volume":"59","author":"Pettus","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib159","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1021\/acs.jmedchem.8b01733","article-title":"Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a potent and selective Pim-1\/2 kinase inhibitor for hematological malignancies","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/anie.198603121","article-title":"The concept of strain in organic chemistry","volume":"25","author":"Wiberg","year":"1986","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118761_bib161","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/ar50134a004","article-title":"Electrophilic cyclopropanes in organic synthesis","volume":"12","author":"Danishefsky","year":"1979","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118761_bib162","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and Re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib163","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-Emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib164","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1021\/acs.jmedchem.4c01308","article-title":"Covalent inhibitors: to infinity and beyond","volume":"67","author":"Raouf","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118761_bib165","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.chemrev.6b00798","article-title":"Cyclopropanation strategies in recent total syntheses","volume":"117","author":"Ebner","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118761_bib166","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0009-2797(01)00161-2","article-title":"Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon","volume":"134","author":"Ulrich","year":"2001","journal-title":"Chem. Biol. Interact."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2026.118761_bib167","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/01926230490451699","article-title":"Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression","volume":"32","author":"Jolly","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejmech.2026.118761_bib168","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/17425255.1.1.91","article-title":"Minimising the potential for metabolic activation in drug discovery","volume":"1","author":"Kalgutkar","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118761_bib169","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:20:35Z","timestamp":1784668835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":169,"alternative-id":["S0223523426002060"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118761","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclopropyl as a versatile tool in the development of kinase-targeted therapeutics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118761"}}